Express News | Third Harmonic Shares Are Trading Higher on Continued Strength After the Company Reported Q2 Financial Results Yesterday. Also, Morgan Stanley Upgraded the Stock From Equal-Weight to Overweight and Raised Its Price Target From $12 to $20
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises to Overweight
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises Target Price to $20.00 From $12.00
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio GAAP EPS of $0.46
Third Harmonic Bio 2Q Net $18.6M >THRD
Express News | Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Express News | Third Harmonic Bio Q2 Net Income USD -10.7 Million
Third Harmonic Bio | 10-Q: Q2 2024 Earnings Report
We're Interested To See How Third Harmonic Bio (NASDAQ:THRD) Uses Its Cash Hoard To Grow
Third Harmonic Bio(THRD.US) Officer Sells US$124.57K in Common Stock
Form 144 | Third Harmonic Bio(THRD.US) Officer Proposes to Sell 125.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Third Harmonic Bio(THRD.US)$ Officer JULIE PERSON intends to sell 10,000 shares of its common stock on Jun 26, with a total market value of approximately $125.4K. JU
Stifel Starts Third Harmonic at Buy, Cites Mast Cell Disease Approach
Express News | Third Harmonic Bio Inc : Stifel Initiates Coverage With Buy Rating; Target Price $23
Express News | Stifel Initiates Coverage On Third Harmonic Bio With Buy Rating, Announces Price Target of $23
Stifel Initiates Third Harmonic Bio(THRD.US) With Buy Rating, Announces Target Price $23
Third Harmonic Bio(THRD.US) Officer Sells US$6,999.98 in Common Stock